BRCA2 and gastric cancer: Shortly thereafter, in a 2001 study involving 70 Ashkenazi Jewish patients with gastrointestinal (GI) malignancies, the BRCA2 Ashkenazi Jewish founder PV (6174delT) was enriched among patients with GC compared to the general Ashkenazi Jewish population (5.7% vs. 1.2%; OR 5.2, 95% CI 1.2–22) [25].